Danielle M. Burgenske
Mayo Clinic
GeneCell cycle checkpointPharmacodynamicsPharmacokineticsCancerInternal medicineDNA repairDNA damageOncologyEfficacyIonizing radiationKinaseChemistryApoptosisIn vitroIn vivoMdm2GlioblastomaLung cancerChemotherapyAntibody-drug conjugateTemozolomideTyrosine phosphorylationMelanomaGliomaBlood–brain barrierBrain tumorAtaxia-telangiectasiaDrugPatient specificTumor xenograftMethylationCancer researchRadiation therapyDNA-PKcsText miningMedicineCell cultureBiologyQuantitative analysis (chemistry)
24Publications
2H-index
42Citations
Publications 24
Newest
#1Begoña Giménez-Cassina López (Brigham and Women's Hospital)H-Index: 11
#2Ishwar N. Kohale (MIT: Massachusetts Institute of Technology)H-Index: 2
Last. Michael S. Regan (Brigham and Women's Hospital)H-Index: 7
view all 28 authors...
Background null Response to targeted therapy varies between patients for largely unknown reasons. Here, we developed and applied an integrative platform using mass spectrometry imaging (MSI), phosphoproteomics, and multiplexed tissue imaging for mapping drug distribution, target engagement, and adaptive response to gain insights into heterogeneous response to therapy. null Methods null Patient derived xenograft (PDX) lines of glioblastoma were treated with adavosertib, a Wee-1 inhibitor, and tis...
Source
#1Danielle M. Burgenske (Mayo Clinic)H-Index: 2
#2Surabhi Talele (UMN: University of Minnesota)H-Index: 1
Last. Gautham Gampa (UMN: University of Minnesota)H-Index: 6
view all 22 authors...
BACKGROUND Glioblastoma (GBM) is an incurable disease with few approved therapeutic interventions. Radiation therapy (RT) and temozolomide (TMZ) remain the standards of care. The efficacy and optimal deployment schedule of the orally bioavailable small-molecule tumor checkpoint controller lisavanbulin alone, and in combination with, standards of care were assessed using a panel of IDH-wildtype GBM patient-derived xenografts. METHODS Mice bearing intracranial tumors received lisavanbulin +/- RT +...
Source
#1Jeanette E. Eckel-Passow (Mayo Clinic)H-Index: 45
#2Gaspar J. Kitange (Mayo Clinic)H-Index: 27
Last. Jann N. Sarkaria (Mayo Clinic)H-Index: 67
view all 7 authors...
Background null Appropriately designed preclinical patient-derived xenograft (PDX) experiments are important to accurately inform human clinical trials. There is little experimental design guidance regarding choosing the number of PDX lines to study, and the number of mice within each PDX line. null Methods null Retrospective data from IDH-wildtype glioblastoma preclinical experiments evaluating a uniform regimen of fractionated radiation (RT), temozolomide (TMZ) chemotherapy, and concurrent RT/...
Source
#1Bianca Maria Marin (Mayo Clinic)H-Index: 1
#2Kendra A Porath (Mayo Clinic)
Last. Jann N. Sarkaria (Mayo Clinic)H-Index: 67
view all 30 authors...
BACKGROUND Antibody drug conjugates (ADCs) targeting the epidermal growth factor receptor (EGFR), such as depatuxizumab mafodotin (Depatux-M), is a promising therapeutic strategy for glioblastoma (GBM) but recent clinical trials did not demonstrate a survival benefit. Understanding the mechanisms of failure for this promising strategy is critically important. METHODS PDX models were employed to study efficacy of systemic vs intracranial delivery of Depatux-M. Immunofluorescence and MALDI-MSI wer...
Source
#1Rachael A. Vaubel (Mayo Clinic)H-Index: 9
#2Ann C. Mladek (Mayo Clinic)H-Index: 19
Last. Jann N. Sarkaria (Mayo Clinic)H-Index: 67
view all 13 authors...
Source
#1Gaspar J. Kitange (Mayo Clinic)H-Index: 27
#2Danielle M. Burgenske (Mayo Clinic)H-Index: 2
Last. Jann N. Sarkaria (Mayo Clinic)H-Index: 67
view all 10 authors...
Source
#1Jianxiong Ji (Mayo Clinic)
#2Emily L. Smith (Mayo Clinic)H-Index: 1
Last. Jann N. Sarkaria (Mayo Clinic)H-Index: 67
view all 22 authors...
Source
#1Ishwar N. Kohale (MIT: Massachusetts Institute of Technology)H-Index: 2
Last. Forest M. White (MIT: Massachusetts Institute of Technology)H-Index: 60
view all 12 authors...
Abstract Formalin fixed paraffin embedded (FFPE) tissues are an invaluable source of clinical specimens. Tyrosine phosphorylation (pTyr) plays a fundamental role in cellular processes and is commonly dysregulated in cancer but has not been studied to date in FFPE samples. We describe a method for quantitative analysis of pTyr signaling networks at an unprecedented sensitivity, with hundreds of sites quantified from 1-2 10-μm sections of FFPE tissue specimens. Phosphotyrosine profiles of flash fr...
Source
#1Ann C. Mladek Tuma (Mayo Clinic)H-Index: 1
#2Shiv K. Gupta (Mayo Clinic)H-Index: 14
Last. Jann N. Sarkaria (Mayo Clinic)H-Index: 67
view all 13 authors...
Robust function of the p53 tumor suppressor pathway is critical when treating with DNA-damage inducing agents such as radiation therapy (RT), which is a key component of standard care for GBM. MDM2 is an important negative regulator of p53 stability and MDM2 is amplified in approximately 14% of GBM. Based on the concept that suppression of MDM2 can reactivate p53 function and potentially have single agent or combinatorial effects, multiple MDM2 inhibitors have been developed. Here we report in v...
Source
#1Jiajia Chen (Mayo Clinic)
#2Shiv K. Gupta (Mayo Clinic)H-Index: 14
Last. Jann N. Sarkaria (Mayo Clinic)H-Index: 67
view all 11 authors...
The efficacy of standard radiation therapy (RT) in glioblastoma (GBM) is limited, and there is a strong rationale to develop effective radiosensitizing agents. ATM is a key regulator of DNA damage induced by RT, and small molecule ATM inhibitors have shown radio-sensitizing effects in cancer cells, and may improve radio-sensitivity in GBM. Here, we evaluated the brain penetrant ATM inhibitor AZD1390 in combination with RT in GBM cell lines and patient derived xenografts (PDXs). AZD1390 (30 nM an...
Source